Need advice in managing cancer immunotherapy cardiotoxicity?

Request Assistance
the link between CANCER and CARDIOVASCULAR CARDIO-
VASCULAR

DISEASE
NEWS
FDA Public Workshop: Assessment of Cardiovascular Toxicities in Immuno-oncology Trials
Posted by Moslehi on January 22, 2018

On Friday, December 1, 2017, the U.S. Food & Drug Administration (FDA) announced a public workshop entitled, “Assessment of Cardiovascular Toxicities in Immuno-oncology Trials”. This workshop provided a forum for discussion of cardiovascular toxicities in immuno-oncology clinical trials. The workshop focused on the identification...

Read More
Manuscripts published in Circulation raise awareness for immune checkpoint inhibitor associated myocarditis
Posted by Moslehi on January 22, 2018

Two manuscripts published on November 21, 2017 of the journal Circulation bring additional awareness for the syndrome of immune checkpoint-inhibitor (ICI)-associated myocarditis. Thuny and colleagues (Hospital Nord, Marseille, France) present a case series of 30 patients with ICI-induced cardiotoxicity. Cardiotoxicity was diagnosed at a...

Read More
Cardio-Oncology highlighted at American Heart Association Annual Meeting 2017
Posted by Moslehi on January 22, 2018

There were several cardio-oncology sessions at the American Heart Association (AHA) annual meeting which occurred in November 2017 in Anaheim, California. A session called “The Emerging Science of Cardio-Oncology” focused on the rapidly evolving area of clinical practice in cancer patients with heart failure or acute coronary...

Read More
View All
connect with us
LATEST TWEETS

VUMC zoom conference 6/3/20! Do you know the CV risks of Prostate tx? Do you know the ABCDE Algorithm for patient care? Free to join, more the merrier! #CardioOnc #oncology #cardiotwitter https://t.co/QKaIYKhZSA

Looking forward to partner w/ @KSchaffer17 & A+ @VUMChealth GU Onc team for #CardioOnc meeting this WED. Overview of new @NEJM studies presented #ASCO20! CV issues in our prostate cancer pts! @KimrynRathmell @benhopark @brian_rini @NBDavisMD @DrTochiOkwuosa @anita_deswal @Myovant

HERO study: Oral GnRH antagonist Relugolix
⭕️Earlier/sustained castration✅
⭕️Post-Tx earlier and better Testosterone recovery✅
⭕️Less major cardiovasc. events✅
⭕️Compliance/cost ?
Neal D. Shore et al. @Daniel_J_George @AlbertoBossial
@ASCO #ASCO20 @OncoAlert @CardioOncology

This is worth reading! Stay tuned for an upcoming VUMC ZOOM presentation 6/3/20 on prostate cancer as well #CardioOnc #oncology #cardiology https://t.co/XwValVhP5C